Emergent BioSolutions Announces Appointment of Seamus Mulligan to its Board of Directors
12 févr. 2019 06h30 HE
|
Emergent BioSolutions
GAITHERSBURG, Md., Feb. 12, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the appointment of Seamus Mulligan to the company’s Board of Directors effective March 19,...
Emergent BioSolutions Announces Daniel J. Abdun-Nabi to Retire as CEO; Robert G. Kramer, Sr. to Become President and CEO
04 janv. 2019 07h00 HE
|
Emergent BioSolutions
GAITHERSBURG, Md., Jan. 04, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that its CEO Daniel J. Abdun-Nabi will be retiring and that its board of directors has...
WABCO Signs $950 Million Long-Term Agreement with Global Manufacturer to Supply its Leading Braking, Advanced Driver Assistance Systems and Efficiency Technologies
20 déc. 2018 06h30 HE
|
WABCO Holdings Inc.
BRUSSELS, Belgium, Dec. 20, 2018 (GLOBE NEWSWIRE) -- WABCO Holdings Inc. (NYSE: WBC) (www.wabco-auto.com), the leading global supplier of braking control systems and other advanced technologies that...
WABCO Signs Long-Term Agreement to Supply a Broad Portfolio of its Advanced Technologies to Support Hyundai Motor Company’s New Medium-Duty Truck Launch in South Korea
08 nov. 2018 06h30 HE
|
WABCO Holdings Inc.
SHANGHAI, China, Nov. 08, 2018 (GLOBE NEWSWIRE) -- WABCO Holdings Inc. (NYSE: WBC) (www.wabco-auto.com), the leading global supplier of braking control systems and other advanced technologies that...
Emergent BioSolutions to Participate in the Goldman Sachs 39th Annual Global Healthcare Conference
08 juin 2018 06h30 HE
|
Emergent BioSolutions
GAITHERSBURG, Md., June 08, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that a member of the company’s senior management team will present a corporate overview and...
Emergent BioSolutions Reports First Quarter 2018 Financial Results
03 mai 2018 16h30 HE
|
Emergent BioSolutions
Reaffirms full year 2018 financial forecast and operational goalsProvides Q2 2018 revenue forecast of $205M-$230M GAITHERSBURG, Md., May 03, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions...
Emergent BioSolutions Awarded One-Year CDC Contract Valued at $26 Million for Vaccinia Immune Globulin Program
28 févr. 2018 06h45 HE
|
Emergent Biosolutions, Inc.
GAITHERSBURG, Md., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced a contract award by the Centers for Disease Control and Prevention (CDC) valued at $26...
Emergent BioSolutions Reports Third Quarter and Nine Months 2017 Financial Results; Raises Calendar Year 2017 Guidance
02 nov. 2017 16h15 HE
|
Emergent Biosolutions, Inc.
GAITHERSBURG, Md., Nov. 02, 2017 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) reported financial results for the quarter and nine months ended September 30, 2017. FINANCIAL HIGHLIGHTS ...
Emergent BioSolutions to Release Third Quarter and Nine Months 2017 Financial Results and Conduct a Conference Call on November 2, 2017
19 oct. 2017 07h00 HE
|
Emergent Biosolutions, Inc.
GAITHERSBURG, Md., Oct. 19, 2017 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS) will release its financial results for the third quarter and nine months of 2017 immediately after market close...
Emergent BioSolutions Reports Second Quarter and Six Months 2017 Financial Results; Reaffirms Calendar Year 2017 Guidance
03 août 2017 16h15 HE
|
Emergent BioSolutions Inc.
GAITHERSBURG, Md., Aug. 03, 2017 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) reported financial results for the quarter and six months ended June 30, 2017. FINANCIAL HIGHLIGHTS (in...